Navigation Links
TGen, Virginia G. Piper Cancer Center scientist heads lung cancer consortium
Date:6/8/2011

SCOTTSDALE, Ariz. June 8, 2011 Dr. Glen Weiss, who holds joint appointments at the Translational Genomics Research Institute (TGen) and at the Virginia G. Piper Cancer Center at Scottsdale Healthcare, is the new Chief Medical Officer of an international lung cancer research consortium.

In this new position, Dr. Weiss heads the Cancer Research and Biostatistics-Clinical Trials Consortium (CRAB-CTC), a Seattle-based cooperative research network, created by a group of preeminent lung cancer investigators. It represents more than 10 institutes worldwide dedicated to funding and facilitating clinical trials, thereby providing lung cancer patients with newly developed therapeutics as quickly as possible.

"Our Consortium's explicit mission is to organize and accelerate the clinical development of new agents for the treatment of patients with lung cancer," said Dr. Weiss, an Assistant Professor of TGen's Cancer and Cell Biology Division. He also is Director of Thoracic Oncology at Virginia G. Piper Cancer Center Clinical Trials, a partnership between TGen and Scottsdale Healthcare that treats cancer patients with promising new drugs through clinical trials at the Virginia G. Piper Cancer Center in Scottsdale, Ariz.

CRAB-CTC members include laboratory and clinical researchers in the U.S., Canada and China who share a passion for bringing new scientific advances to patients with lung cancer as rapidly as possible.

"Our Consortium provides a well-coordinated effort dedicated to rapidly translating research discoveries into new treatments and supportive care for patients with lung cancer," said Dr. Weiss.

Unlike similar research consortiums, CRAB-CTC is not affiliated or funded by government, but works directly with pharmaceutical firms to advance their compounds.

"CRAB's mission is to help conquer cancer. The network provided by the CRAB-CTC enables research oncologists to design and conduct innovative studies more quickly, in more places and with greater degree of opportunity for specific patient needs," said Dr. John Crowley, CEO of CRAB and lead statistician for multiple cancer clinical trials.

"What this will mean for patients, is that we will be able to offer patients new therapies much faster," Dr. Weiss said.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims
2. Virginia Tech mechanical engineers win measurement science best paper award
3. Virginia Tech announces football helmet ratings for reducing concussion risk
4. Young scientist at Virginia Commonwealth University wins Avanti prize
5. Virginia Tech forest researcher awarded NSF early career grant
6. Virginia Tech researcher seeks to use electrical stimulation to give voice to stroke patients
7. Virginia Tech shares in grant to study effects of climate change on southern pine forests
8. Virginia Tech engineer identifies new concerns for antibiotic resistance, pollution
9. Virginia Tech engineers introduce thermotherapy as a chemotherapy alternative
10. USDA awards Virginia Tech $3.8 million to stimulate eastern US wine industry
11. Virginia Tech studies impact of Gulf oil spill on plovers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
(Date:3/20/2017)... PMD Healthcare announces the release of its ... System (WMS), a remote, real-time lung health monitoring and ... is a Medical Device, Digital Health, and Chronic Care ... innovative solutions that empower people to improve their healthcare ... developed the first ever personal spirometer, Spiro PD, which ...
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. , March ... Made Simple," and 23andMe , the leading personal ... food choices.  Zipongo can now provide customers with personalized ... health goals and biometrics, but also genetic markers impacting ... Zipongo,s personalized food decision support platform uses ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... 22, 2017  UBM and the Massachusetts Medical ... extended partnership and the third annual Massachusetts Medtech Week. ... 21 st Annual MassMEDIC Conference held in ... 3-4, 2017. MassMEDIC will feature ... President and CEO, Scott Whitaker , at ...
(Date:3/22/2017)... MarketNewsUpdates.com News Commentary  ... The traditional ways to ... as of late due to the rise of the opioid ... dramatic impact on patient,s quality of life as Biotech and ... new forms of opioid formulations that prevent abuse. Biotech and ...
(Date:3/22/2017)... , ... March 21, 2017 , ... Okyanos Cell Therapy ... as part of their live events series, “Stem Cell Therapy: The Next Phase in ... under the 2013 Stem Cell Research and Therapy Act, Okyanos maintains a ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... its innovative Quantum peristaltic pump with patented ReNu single-use (SU) cartridge technology. ... standard for high-pressure feed pumps in SU tangential flow filtration (TFF), virus ...
Breaking Biology Technology: